Topoisomerase I-Mediated Inhibition of Hypoxia-Inducible Factor 1: Mechanism and Therapeutic Implications

Cancer Research

Volumn 64, Issue 4, 2004, Pages 1475-1482

  Rapisarda, Annamaria ^a   Uranchimeg, Badarch ^a   Sordet, Olivier ^b   Pommier, Yves ^b   Shoemaker, Robert H ^a   Melillo, Giovanni ^a,c  

^a SAIC FREDERICK INC   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APHIDICOLIN; CAMPTOTHECIN DERIVATIVE; DNA TOPOISOMERASE; DOXORUBICIN; HYPOXIA INDUCIBLE FACTOR 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MESSENGER RNA; TOPOTECAN;

ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DNA DAMAGE; DNA REPLICATION; DOSE TIME EFFECT RELATION; DRUG INHIBITION; DRUG MECHANISM; DRUG POTENTIATION; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GLIOMA CELL; HALF LIFE TIME; HUMAN; HUMAN CELL; IONIZING RADIATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA TRANSCRIPTION; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; TRANSLATION REGULATION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; CELL LINE, TUMOR; CYSTEINE ENDOPEPTIDASES; DNA DAMAGE; DNA REPLICATION; DNA TOPOISOMERASES, TYPE I; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MULTIENZYME COMPLEXES; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN BIOSYNTHESIS; PROTEIN KINASES; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; RNA, MESSENGER; TOPOTECAN; TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC;

EID: 1242271198     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-03-3139     Document Type: Article

References (47)

1. 2 tension. Proc. Natl. Acad. Sci. USA, 92: 5510-5514, 1995.
2. Semenza, G. L. HIF-1 and tumor progression: pathophysiology and therapeutics. Trends Mol. Med., 8: S62-67, 2002.
3. 2 sensing. Science (Wash. DC), 292: 464-468, 2001.
4. 2-regulated prolyl hydroxylation. Science (Wash. DC), 292: 468-472, 2001.
5. Masson, N., Willam, C., Maxwell, P. H., Pugh, C. W., and Ratcliffe, P. J. Independent function of two destruction domains in hypoxia-inducible factor-α chains activated by prolyl hydroxylation. EMBO J., 20: 5197-5206, 2001.
6. Bruick, R. K., and McKnight, S. L. A conserved family of prolyl-4-hydroxylases that modify HIF. Science (Wash. DC), 294: 1337-1340, 2001.
7. Epstein, A. C., Gleadle, J. M., McNeill, L. A., Hewitson, K. S., O'Rourke, J., Mole, D. R., Mukherji, M., Metzen, E., Wilson, M. I., Dhanda, A., Tian, Y. M., Masson, N., Hamilton, D. L., Jaakkola, P., Barstead, R., Hodgkin, J., Maxwell, P. H., Pugh, C. W., Schofield, C. J., and Ratcliffe, P. J. C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell, 107: 43-54, 2001.
8. Jeong, J. W., Bae, M. K., Ahn, M. Y., Kim, S. H., Sohn, T. K., Bae, M. H., Yoo, M. A., Song, E. J., Lee, K. J., and Kim, K. W. Regulation and destabilization of HIF-1α by ARD1-mediated acetylation. Cell, 111: 709-720, 2002.
9. Semenza, G. L. Targeting HIF-1 for cancer therapy. Nat. Rev. Cancer, 3: 721-732, 2003.
10. Zhong, H., Chiles, K., Feldser, D., Laughner, E., Hanrahan, C., Georgescu, M. M., Simons, J. W., and Semenza, G. L. Modulation of hypoxia-inducible factor 1α expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res., 60: 1541-1545, 2000.
11. Laughner, E., Taghavi, P., Chiles, K., Mahon, P. C., and Semenza, G. L. Her2 (neu) signaling increases the rate of hypoxia-inducible factor 1α (HIF-1α) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Mol. Cell Biol., 21: 3995-4004, 2001.
12. Fukuda, R., Hirota, K., Fan, F., Jung, Y. D., Ellis, L. M., and Semenza, G. L. Insulin-like growth factor 1 induces hypoxia-inducible factor 1-mediated vascular endothelial growth factor expression, which is dependent on MAP kinase and phosphatidylinositol 3-kinase signaling in colon cancer cells. J. Biol. Chem., 277: 38205-38211, 2002.
13. Feldser, D., Agani, F., Iyer, N. V., Pak, B., Ferreira, G., and Semenza, G. L. Reciprocal positive regulation of hypoxia-inducible factor 1á and insulin-like growth factor 2. Cancer Res., 59: 3915-3918, 1999.
14. Zelzer, E., Levy, Y., Kahana, C., Shilo, B. Z., Rubinstein, M., and Cohen, B. Insulin induces transcription of target genes through the hypoxia-inducible factor HIF-1α/ARNT. EMBO J., 17: 5085-5094, 1998.
15. Zundel, W., Schindler, C., Haas-Kogan, D., Koong, A., Kaper, F., Chen, E., Gottschalk, A. R., Ryan, H. E., Johnson, R. S., Jefferson, A. B., Stokoe, D., and Giaccia, A. J. Loss of PTEN facilitates HIF-1-mediated gene expression. Genes Dev., 14: 391-396, 2000.
16. Zhong, H., De Marzo, A. M., Laughner, E., Lim, M., Hilton, D. A., Zagzag, D., Buechler, P., Isaacs, W. B., Semenza, G. L., and Simons, J. W. Overexpression of hypoxia-inducible factor 1α in common human cancers and their metastases. Cancer Res., 59: 5830-5835, 1999.
17. Aebersold, D. M., Burri, P., Beer, K. T., Laissue, J., Djonov, V., Greiner, R. H., and Semenza, G. L. Expression of hypoxia-inducible factor-1α: a novel predictive and prognostic parameter in the radiotherapy of oropharyngeal cancer. Cancer Res., 61: 2911-2916, 2001.
18. Bimer, P., Schindl, M., Obermair, A., Plank, C., Breitenecker, G., and Oberhuber, G. Overexpression of hypoxia-inducible factor 1α is a marker for an unfavorable prognosis in early-stage invasive cervical cancer. Cancer Res., 60: 4693-4696, 2000.
19. Birner, P., Schindl, M., Obermair, A., Breitenecker, G., and Oberhuber, G. Expression of hypoxia-inducible factor 1α in epithelial ovarian tumors: its impact on prognosis and on response to chemotherapy. Clin. Cancer Res., 7: 1661-1668, 2001.
20. Birner, P., Gatterbauer, B., Oberhuber, G., Schindl, M., Rossler, K., Prodinger, A., Budka, H., and Hainfellner, J. A. Expression of hypoxia-inducible factor-1α in oligodendrogliomas: its impact on prognosis and on neoangiogenesis. Cancer (Phila.), 92: 165-171, 2001.
21. Koukourakis, M. I., Giatromanolaki, A., Skarlatos, J., Corti, L., Blandamura, S., Piazza, M., Gatter, K. C., and Harris, A. L. Hypoxia-inducible factor (HIF-1a and HIF-2a) expression in early esophageal cancer and response to photodynamic therapy and radiotherapy. Cancer Res., 61: 1830-1832, 2001.
22. Krishnamachary, B., Berg-Dixon, S., Kelly, B., Agani, F., Feldser, D., Ferreira, G., Iyer, N., LaRusch, J., Pak, B., Taghavi, P., and Semenza, G. L. Regulation of colon carcinoma cell invasion by hypoxia-inducible factor 1. Cancer Res., 63: 1138-1143, 2003.
23. Pennacchietti, S., Michieli, P., Galluzzo, M., Mazzone, M., Giordano, S., and Comoglio, P. M. Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell, 3: 347-361, 2003.
24. Rapisarda, A., Uranchimeg, B., Scudiero, D. A., Selby, M., Sausville, E. A., Shoemaker, R. H., and Melillo, G. Identification of small molecule inhibitors of hypoxia-inducible factor 1 transcriptional activation pathway. Cancer Res., 62: 4316-4324, 2002.
25. Fujimori, A., Harker, W. G., Kohlhagen, G., Hoki, Y., and Pommier, Y. Mutation at the catalytic site of topoisomerase I in CEM/C2, a human leukemia cell line resistant to camptothecin. Cancer Res., 55: 1339-1346, 1995.
26. Melillo, G., Musso, T., Sica, A., Taylor, L. S., Cox, G. W., and Varesio, L. A hypoxia-responsive element mediates a novel pathway of activation of the inducible nitric oxide synthase promoter. J. Exp. Med., 182: 1683-1693, 1995.
27. Wang, G. L., and Semenza, G. L. Desferrioxamine induces erythropoietin gene expression and hypoxia-inducible factor 1 DNA-binding activity: implications for models of hypoxia signal transduction. Blood, 82: 3610-3615, 1993.
28. Hudson, C. C., Liu, M., Chiang, G. G., Otterness, D. M., Loomis, D. C., Kaper, F., Giaccia, A. J., and Abraham, R. T. Regulation of hypoxia-inducible factor 1α expression and function by the mammalian target of rapamycin. Mol. Cell Biol., 22: 7004-7014, 2002.
29. Nakashio, A., Fujita, N., Rokudai, S., Sato, S., and Tsuruo, T. Prevention of phosphatidylinositol 3′-kinase-Akt survival signaling pathway during topotecan-induced apoptosis. Cancer Res., 60: 5303-5309, 2000.
30. Melillo, G., Taylor, L. S., Brooks, A., Musso, T., Cox, G. W., and Varesio, L. Functional requirement of the hypoxia-responsive element in the activation of the inducible nitric oxide synthase promoter by the iron chelator desferrioxamine. J. Biol. Chem., 272: 12236-12243, 1997.
31. Urasaki, Y., Takebayashi, Y., and Pommier, Y. Activity of a novel camptothecin analogue, homocamptothecin, in camptothecin-resistant cell lines with topoisomerase I alterations. Cancer Res., 60: 6577-6580, 2000.
32. Jaxel, C., Kohn, K. W., Wani, M. C., Wall, M. E., and Pommier, Y. Structure-activity study of the actions of camptothecin derivatives on mammalian topoisomerase I: evidence for a specific receptor site and a relation to antitumor activity. Cancer Res., 49: 1465-1469, 1989.
33. Cushman, M., Jayaraman, M., Vroman, J. A., Fukunaga, A. K., Fox, B. M., Kohlhagen, G., Strumberg, D., and Pommier, Y. Synthesis of new indeno[1, 2-c]-isoquinolines: cytotoxic non-camptothecin topoisomemse I inhibitors. J. Med. Chem., 43: 3688-3698, 2000.
34. Holm, C., Covey, J. M., Kerrigan, D., and Pommier, Y. Differential requirement of DNA replication for the cytotoxicity of DNA topoisomerase I and II inhibitors in Chinese hamster DC3F cells. Cancer Res., 49: 6365-6368, 1989.
35. Wu, J., and Liu, L. F. Processing of topoisomerase I cleavable complexes into DNA damage by transcription. Nucleic Acids Res., 25: 4181-4186, 1997.
36. Desai, S. D., Zhang, H., Rodriguez-Bauman, A., Yang, J. M., Wu, X., Gounder, M. K., Rubin, E. H., and Liu, L. F. Transcription-dependent degradation of topoisomerase I-DNA covalent complexes. Mol. Cell Biol., 23: 2341-2350, 2003.
37. Bendixen, C., Thomsen, B., Alsner, J., and Westergaard, O. Camptothecin-stabilized topoisomerase I-DNA adducts cause premature termination of transcription. Biochemistry, 29: 5613-5619, 1990.
38. Daoud, S. S., Munson, P. J., Reinhold, W., Young, L., Prabhu, V. V., Yu, Q., LaRose, J., Kohn, K. W., Weinstein, J. N., and Pommier, Y. Impact of p53 knockout and topotecan treatment on gene expression profiles in human colon carcinoma cells: a pharmacogenomic study. Cancer Res., 63: 2782-2793, 2003.
39. Lang, K. J., Kappel, A., and Goodall, G. J. Hypoxia-inducible factor-1α mRNA contains an internal ribosome entry site that allows efficient translation during normoxia and hypoxia. Mol. Biol. Cell. 13: 1792-1801, 2002.
40. Kohn, K. W., Shao, R. G., and Pommier, Y. How do drug-induced topoisomerase I-DNA lesions signal to the molecular interaction network that regulates cell cycle checkpoints, DNA replication, and DNA repair? Cell Biochem. Biophys., 33: 175-180, 2000.
41. Liu, L. F., Desai, S. D., Li, T. K., Mao, Y., Sun, M., and Sim, S. P. Mechanism of action of camptothecin. Ann. N. Y. Acad. Sci., 922: 1-10, 2000.
42. Li, T. K., and Liu, L. F. Tumor cell death induced by topoisomerase-targeting drugs. Annu. Rev. Pharmacol. Toxicol., 41: 53-77, 2001.
43. Chao, S. H., and Price, D. H. Flavopiridol inactivates P-TEFb and blocks most RNA polymerase II transcription in vivo. J. Biol. Chem., 276: 31793-31799, 2001.
44. Jung, Y. J., Isaacs, J. S., Lee, S., Trepel, J., and Neckers, L. Microtubule disruption utilizes an NFκB-dependent pathway to stabilize HIF-1á protein. J. Biol. Chem., 278: 7445-7452, 2003.
45. Svejstrup, J. Q. Rescue of arrested RNA polymerase II complexes. J. Cell Sci., 116: 447-451, 2003.
46. Kuznetsova, A. V., Meller, J., Schnell, P. O., Nash, J. A., Ignacak, M. L., Sanchez, Y., Conaway, J. W., Conaway, R. C., and Czyzyk-Krzeska, M. F. von Hippel-Lindau protein binds hyperphosphorylated large subunit of RNA polymerase II through a proline hydroxylation motif and targets it for ubiquitination. Proc. Natl. Acad. Sci. USA, 100: 2706-2711, 2003.
47. Brown, J. M., and Giaccia, A. J. The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Res., 58: 1408-1416, 1998.